1. Academic Validation
  2. Valacyclovir inhibits recovery of ocular HSV-1 after experimental reactivation by excimer laser keratectomy

Valacyclovir inhibits recovery of ocular HSV-1 after experimental reactivation by excimer laser keratectomy

  • Cornea. 1999 Nov;18(6):693-9. doi: 10.1097/00003226-199911000-00012.
D K Dhaliwal 1 E G Romanowski K A Yates D A Barnhorst M Goldstein R G Deeter D N Fish Y J Gordon
Affiliations

Affiliation

  • 1 Department of Ophthalmology, University of Pittsburgh School of Medicine, Pennsylvania 15203, USA. [email protected]
Abstract

Purpose: The goal of this was to determine whether the systemic administration of valacyclovir (Valtrex) would reduce ocular shedding of herpes simplex virus 1 (HSV-1) after excimer laser ablation in the New Zealand rabbit latency model.

Methods: The in vitro 50% inhibitory concentration (IC50) of HSV-1 W strain was determined by using a plaque-reduction assay to verify its sensitivity to acyclovir. Forty-seven NZW rabbits latently infected with HSV-1 W strain were divided into four groups: I, 50 mg/kg/day valacyclovir; II, 100 mg/kg/day valacyclovir; III, 150 mg/kg/day valacyclovir; and IV, saline control. One half of the total dose of valacyclovir was delivered via intraperitoneal injections twice daily for 7 days beginning with one dose before excimer laser keratectomy. HSV-1 ocular shedding was determined from eye cultures for 7 days after treatment.

Results: The IC50 for HSV-1 W was determined to be 2.9 microg/ml. The administration of both 100 mg/kg/day (group II) and 150 mg/kg/day (group III) of valacyclovir significantly reduced the number of eyes from which latent HSV-1 was recovered compared with the control group. There was no difference between the control group and group I (50 mg/kg/day valacyclovir). However, all three valacyclovir dosages significantly reduced the total number of HSV-1 shedding days compared with the control group, and 100% HSV-1 TG latency was demonstrated for all four groups.

Conclusion: Systemic administration of valacyclovir significantly reduced HSV-1 ocular shedding in a dose-dependent manner after excimer laser keratectomy in the NZW rabbit latency model.

Figures
Products